Operating Income (Loss) in USD of Coherus BioSciences, Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Coherus BioSciences, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2012 to Q3 2025.
  • Coherus BioSciences, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$44.3M, a 5.39% increase year-over-year.
  • Coherus BioSciences, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$181M, a 23.4% increase year-over-year.
  • Coherus BioSciences, Inc. annual Operating Income (Loss) for 2024 was -$200M, a 7.48% increase from 2023.
  • Coherus BioSciences, Inc. annual Operating Income (Loss) for 2023 was -$216M, a 16% increase from 2022.
  • Coherus BioSciences, Inc. annual Operating Income (Loss) for 2022 was -$257M, a 2.65% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Coherus BioSciences, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$181M -$44.3M +$2.52M +5.39% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$183M -$45.5M -$5.86M -14.8% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$177M -$45.4M +$22.4M +33% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 -$200M -$45.4M +$36.1M +44.3% 01 Oct 2024 31 Dec 2024 8-K 13 Nov 2025
Q3 2024 -$236M -$46.9M -$14.9M -46.4% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$221M -$39.6M -$5.08M -14.7% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$216M -$67.8M -$42K -0.06% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 -$216M -$81.5M -$30M -58.3% 01 Oct 2023 31 Dec 2023 8-K 13 Nov 2025
Q3 2023 -$186M -$32M +$48.4M +60.2% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$234M -$34.5M +$9.47M +21.5% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$244M -$67.7M +$13.2M +16.3% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$257M -$51.5M -$11.9M -30.2% 01 Oct 2022 31 Dec 2022 10-K 17 Mar 2025
Q3 2022 -$245M -$80.4M -$47.7M -145% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023
Q2 2022 -$197M -$44M -$19.8M -82.1% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023
Q1 2022 -$177M -$80.9M +$86.4M +51.6% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023
Q4 2021 -$264M -$39.5M -$56M -341% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2024
Q3 2021 -$208M -$32.8M -$66.5M -197% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022
Q2 2021 -$141M -$24.2M -$89.5M -137% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 -$51.9M -$167M -$208M -510% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 $156M $16.4M -$28.6M -63.5% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023
Q3 2020 $185M $33.7M -$18.1M -35% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 $203M $65.3M +$37.8M +138% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $165M $40.9M +$57.5M 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $108M $45M +$106M 01 Oct 2019 31 Dec 2019 10-K 23 Feb 2022
Q3 2019 $2.23M $51.8M +$109M 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$107M $27.5M +$72.4M 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 -$179M -$16.6M +$25.4M +60.5% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$204M -$60.5M -$14M -30.2% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021
Q3 2018 -$190M -$57M -$357K -0.63% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019
Q2 2018 -$190M -$44.9M +$11.7M +20.7% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019
Q1 2018 -$202M -$42M +$30.4M +42% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$232M -$46.5M +$27M +36.7% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020
Q3 2017 -$259M -$56.6M -$141M -167% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018
Q2 2017 -$118M -$56.6M +$6.1M +9.72% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018
Q1 2017 -$124M -$72.4M -$8.07M -12.5% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$116M -$73.5M -$21.3M -40.7% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019
Q3 2016 -$94.7M $84.6M +$156M 01 Jul 2016 30 Sep 2016 10-Q 06 Nov 2017
Q2 2016 -$251M -$62.7M -$3.84M -6.52% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017
Q1 2016 -$247M -$64.4M -$27.6M -75.1% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 -$219M -$52.2M -$25.6M -96.6% 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2018
Q3 2015 -$193M -$71.2M -$64.8M -1009% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016
Q2 2015 -$129M -$58.9M -$41M -228% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016
Q1 2015 -$87.7M -$36.7M -$23M -167% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 -$64.7M -$26.6M 01 Oct 2014 31 Dec 2014 10-K 14 Mar 2017
Q3 2014 -$6.42M +$360K +5.31% 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015
Q2 2014 -$17.9M 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015
Q1 2014 -$13.8M 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015
Q3 2013 -$6.78M 01 Jul 2013 30 Sep 2013 10-Q 15 Dec 2014

Coherus BioSciences, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$200M +$16.1M +7.48% 01 Jan 2024 31 Dec 2024 8-K 13 Nov 2025
2023 -$216M +$41.1M +16% 01 Jan 2023 31 Dec 2023 8-K 13 Nov 2025
2022 -$257M +$6.98M +2.65% 01 Jan 2022 31 Dec 2022 10-K 17 Mar 2025
2021 -$264M -$420M -269% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2024
2020 $156M +$48.6M +45.1% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023
2019 $108M +$312M 01 Jan 2019 31 Dec 2019 10-K 23 Feb 2022
2018 -$204M +$27.7M +11.9% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 -$232M -$116M -100% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 -$116M +$103M +47.1% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019
2015 -$219M -$154M -239% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018
2014 -$64.7M -$28.7M -79.7% 01 Jan 2014 31 Dec 2014 10-K 14 Mar 2017
2013 -$36M +$2.53M +6.56% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016
2012 -$38.5M 01 Jan 2012 31 Dec 2012 10-K 23 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.